Navigation Links
Scripps Florida scientist awarded $2.2 million grant to study hepatitis C
Date:10/11/2011

JUPITER, FL, October 10, 2011 The Scripps Research Institute has been awarded a $2.2 million grant by the National Institutes of Health (NIH) to determine how the hepatitis C virus (HCV) induces liver cancer. The research could lead to potentially new therapeutic targets for treating those chronically infected with the virus.

Timothy Tellinghuisen, an assistant professor on the Florida campus of Scripps Research, is the principal investigator for the project.

Hepatitis C virus infection is a major public health problem worldwide. Estimates place the number of HCV infected individuals at approximately 170 to 200 million, representing nearly three percent of the world's population, according to the World Health Organization. HCV infection and its assorted pathologies are responsible for an estimated 250,000 deaths a year worldwide.

A majority of patients remain chronically infected, which can lead to progressive liver damage, cirrhosis, and often the development of hepatocellular carcinomaliver cancer. An estimated 60 to 70 percent of all those infected develop chronic infections and most progress to major liver damage. Each year, as many as five percent of these chronically infected patients will develop liver cancer.

While the mechanisms by which HCV induces liver cancer are largely unknown, Tellinghuisen's ongoing research points to host cell signaling pathways that are likely altered by the virus, creating a replication niche for the virus that avoids the body's innate immune system.

"We have identified a host proteincalled CARD14as an important factor for HCV RNA replication," he said. "We believe that a pathway regulated by this protein gets manipulated by the virus to maintain chronic infections and that this contributes, in part, to liver cancer development. The new grant will help us explore the extensive role of CARD14 in HCV replication and, quite possibly, identify new ways to attack chronic HCV infection."

Overall, the new grant will enable Tellinghuisen and his colleagues to characterize how the virus manipulates this host cell pathway, identify the genes regulated by this pathway and determine their effect on viral infection and persistence, and define the function of this protein in normal liver physiology.


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert  

Related medicine news :

1. Scripps Health Begins Pioneering Study of Human Tumor Sequencing in Cancer Patients
2. Top Scientists Explore the Origin of Life in Annual Lasker Lecture at Scripps Research Institute Florida Campus
3. Scripps Blood & Marrow Transplant Program Celebrates 30th Anniversary of Providing Life-Saving Care
4. Scripps Memorial Hospital La Jolla First in San Diego to Achieve Magnet Nursing Re-designation
5. Scripps Announces Plans for Region's First Proton Therapy Center; $185 Million Facility to Offer Advanced Care to Cancer Patients
6. Scripps Research scientists share $2 million in Florida state research grants
7. Scripps Center for Executive Health Now Offers Genetic Testing
8. Scripps Research scientists uncover previously unknown natural mechanism that controls cocaine use
9. NIH awards Scripps Florida scientists $2.3 Million to develop drug addiction treatments
10. Scripps Research scientists solve long-standing mystery of protein quality control mechanism
11. Scripps and Trius team up to develop new antibiotics with US Department of Defense grant
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Florida scientist awarded $2.2 million grant to study hepatitis C
(Date:5/24/2016)... Linda, CA (PRWEB) , ... May 24, 2016 ... ... fluorescent cell imaging; high content imaging; multiplex immunoassays are widely used for cell ... important for labs to maximize their quality and efficiency in these areas. , ...
(Date:5/23/2016)... ... 23, 2016 , ... On the occasion of his 25th Anniversary of changing ... loss process: , New patients have a consultation and evaluation (done by Dr. Ferdico ... , Body Composition Analysis, There are 15 things that each patient gets checked for, ...
(Date:5/23/2016)... ... 23, 2016 , ... According to an article published May 11th ... birth of her son, Rockwell Lloyd Liu, and notes that gestational surrogacy helped make ... Bill” star explains that, as a career oriented single woman, gestational surrogacy made parenthood ...
(Date:5/23/2016)... ... May 23, 2016 , ... NYDNRehab, a New York City-based ... athletes. This is the first time this type of technology, which was developed by ... to the public in New York. , With over 10 million sport injuries ...
(Date:5/23/2016)... ... May 23, 2016 , ... California State University Northridge ... quality of life and is currently focusing on ways to improve how people ... tested through research to find out whether watching them could have a significant ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... SAN FRANCISCO, Calif. , May 19, 2016 /PRNewswire/ ... a biopharmaceutical company developing novel therapeutics for the treatment ... announced that new GBT440 data will be presented in ... 21 st Congress in Copenhagen ... ongoing Phase 1/2 GBT440-001 study in sickle cell disease ...
(Date:5/19/2016)... 2016 BioLineRx Ltd. (NASDAQ/TASE: BLRX) ... treatment of multiple cancer and hematological indications, will be ... abstract titled " Clinical response in relapsed/refractory AML patients ... BL-8040, a potent CXCR4 antagonist; results of a Phase ... at the European Hematology Association 21st Congress, to be ...
(Date:5/19/2016)... CAMBRIDGE, Massachusetts , May 19, 2016 ... pharmaceuticals and diagnostics based on the gut microbiome, is pleased ... Cambridge, MA to support its operations ... office is located at Kendall Square, the heart of ... global hub for transforming scientific insights into new drugs. The ...
Breaking Medicine Technology: